<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>  <br /> Identification functional analysis SKA2 interaction <span id='am-40' about='obo:IMR_0100036' typeof='owl:Thing obo:IMR_0100033 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0000966 obo:IMR_0000001'><span id='am-41' property="oboInOwl:id" content="IMR:0100036" datatype="xsd:string"></span><span id='am-42' property="rdfs:label" content="glucocorticoid" datatype="xsd:string"></span><span id='am-43' property="oboInOwl:hasDbXref" content="KEGG:C00735" datatype="xsd:string"></span><span id='am-44' property="rdfs:label" content="stress hormone" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:hasDbXref" content="KEGG:C05490" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasExactSynonym" content="stress hormone" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:hasDbXref" content="KEGG:C00762" datatype="xsd:string"></span><span id='am-48' property="oboInOwl:hasDbXref" content="KEGG:C02140" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>glucocorticoid</span> receptor <br />  <br /> Abstract <br /> Glucocorticoid (GC) receptors (GRs) profound anti-                         overexpression increased GC transactivation HepG2 cells <br /> survival effects human small cell lung cancer (SCLC).                     SKA2 knockdown A549 human lung epithelial cells <br /> explore basis effects, protein partners GRs               decreased transactivation prevented dexamethasone inhi- <br /> sought using yeast hybrid screen. discovered novel                   bition proliferation. GC treatment decreased SKA2 protein <br /> gene, FAM33A, subsequently identified SKA1 partner                     levels A549 cells, did Staurosporine, phorbol ester involved mitosis, renamed Ska2. produced anti-                  trichostatin  agents inhibit cell proliferation.  <br /> <span id='am-1' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-2' property="rdfs:label" content="peptide" datatype="xsd:string"></span><span id='am-3' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span>peptide</span> antibody specifically recognized length human                 expression SKA2 potentiated proliferative response SKA2 measure expression human cell lines tissues.                     IGF exposure, knockdown shRNA caused cells wide variation expression multiple cell lines,            arrest mitosis. SKA2 recently identified HeLa S3 detected liver cell line HepG2. xenograft                 cells complex, critical spindle checkpoint <br /> model human SCLC intense staining archival tissue                    silencing exit mitosis. new data involvement <br /> revealed SKA2 human lung breast tumours. SKA2                    cell proliferation GC signalling, implications cytoplasm, localized GR,                  understanding GCs impact cell fate. <br /> nuclear expression SKA2 seen breast tumours. SKA2                     Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509 <br />  <br />  <br />  <br />  <br /> Introduction                                                                    responsible mediating GR action, e.g. activator <br />                                                                                 protein 1 (AP-1; Gottlicher et al. 1998). <br /> Glucocorticoids (GC) act GC receptor (GR),                           GCs widely used initial treatment patients member nuclear receptor superfamily ligand-                           lung cancer, primarily anti-emetic anti- <br /> regulated transcription factors (Hollenberg et al. 1985,                        inflammatory effects, direct anti-tumour action Weinberger et al. 1985, 1987, Perlmann <span id='am-6' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-7' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-8' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-9' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span>amp</span>; Evans 1997,                            proposed (Sommer et al. 2007). profound <br /> Margolis et al. 2005, Bookout et al. 2006). activation,                  inhibitory effects cell cycle progression cell proliferation <br /> GR capable upregulating downregulating target                    human lung cancer cell lines (Hofmann et al. 1995). GCs, <br /> gene expression (Ray et al. 1999). final functional effect                  dexamethasone (Dex), shown activated GR given cell critically determined                 anti-tumourigenic effects mouse models lung cancer <br /> interactions spectrum modulator proteins                           (Witschi et al. 2005). mode action model (Lonard et al. 2004, O&#226;&#8364;&#8482;Malley 2004, Wu et al. 2005).                    unclear thought GCs affect cell differentiation. <br /> canonical nuclear receptor interaction motifs                          Alternatively, GCs acting lung cancer models recognized, including LxxLL LIM domains (Cheskis                            inhibiting cell proliferation, given effects human lung <br /> et al. 2003, Kassel et al. 2004), addition,                        cancer cells (Hofmann et al. 1995). characterized small <br /> interacting partners defined peptide motifs,                        cell lung carcinoma (SCLC) cells deficient GR <br /> e.g. RelA (Nissen &amp; Yamamoto 2000, Garside et al. 2004).                        expression resistant GC action (Ray et al. 1994, modulator families primarily alter                             Hofmann et al. 1995, Sommer et al. 2007). Importantly, <br /> amplitude GR effect, e.g. steroid receptor coactivator                   overexpression GR cells powerfully induced <br /> 1; (SRC1; Stevens et al. 2003), GR-interacting proteins                   apoptosis (Sommer et al. 2007), suggesting acquisition  <br /> Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509                                                                                     DOI: 10.1677/JOE-08-0019 <br /> 0022&#226;&#8364;&#8220;0795/08/0198&#226;&#8364;&#8220;499 q 2008 Society Endocrinology Printed Great Britain                     Online version http://www.endocrinology-journals.org Open Access article distributed terms Society Endocrinology&#226;&#8364;&#8482;s use Licence permits unrestricted non-commercial use, <br /> distribution, reproduction medium, provided original work properly cited. <br />  500   L RICE   . SKA2 interactions GR <br />  <br />       GC resistance survival mechanism human SCLC              AtT20 cells obtained ECCAC cultured       (Sommer et al. 2007).  GR potentially informative   described (Ray et al. 1996b). <br />       node novel pathogenic mechanisms lung cancer.                cells cultured normal growth medium <br />          aim novel GR-interacting proteins              supplemented 10% charcoal dextran-stripped FCS <br />       expressed characterized SCLC cells,             (HyClone, Logan, UT, USA) treatment Dex. <br />       provide new insights cellular mechanisms <br />       associated proliferative potential. Using yeast <br />                                                                         Yeast hybrid screen <br />       hybrid screen identified specific interaction <br />       GR FAM33A, recently                    yeast hybrid screen reported       identified SKA2, conserved protein involved           (Garside et al. 2006). <br />       kinetochore complex (Hanisch et al. 2006). Depletion       SKA2 small interfering RNAs causes cells                                                                         DNA constructs <br />       suspended metaphase-like state. delays exit       mitosis onset anaphase.  authors         pcDNA3GR plasmid previously described (Ray <br />       propose SKA complex required stabilizing          et al. 1999). TAT3-luc plasmid kind gift Prof. <br />       kinetochore-microtubule attachments checkpoint             Keith Yamamoto Dr Jorge Iniguez-Lluhi (Department       silencing.                                                        Cellular Molecular Pharmacology, University Cali- <br />          studies presented identification SKA2    fornia, San Francisco) (Iniguez-Lluhi et al. 1997). cMyc- <br />       human tumour cell lines, interaction GR      SKA2 construct contained open reading frame inserted <br />       impact depletion SKA2 apoptotic- proliferation-      N-terminal cMyc tagged vector cytomegalovirus <br />       associated genes suggest SKA2 play role regulation    (CMV)-Tag3B (Stratagene). GST-SKA2 fusion plasmid       lung cancer cell proliferation.                                   inserting SKA2 cDNA pGEX-5X-1 vector <br />                                                                         (Amersham Pharmacia Biotech). <br />                                                                            SKA2 shRNA vectors using vector pSUPER <br />                                                                         (Oligoengine, Seattle, WA, USA). Sense antisense oligonu- <br />       Materials Methods                                             cleotide sequences (MWG Biotech AG, London, <br />                                                                         UK). Knockdown sequence: 5 0 -GATCCCCGGCTGGAA- <br />       Compounds <br />                                                                         TATGAAATCAATTCAAGAGATTGATTTCATATTCCA- <br />       Dex, phorbol 12-myristate 13-acetate, Forskolin, trichostatin     GCCTTTTTCGAAA-3 0 scrambled bp control: 5 0 - <br />       (TSA) insulin-like growth factor (IGF         GATCCCCTTCTCCGAACGTGTCACGTTTCAAGAG- <br />       Sigma&#226;&#8364;&#8220;Aldrich; mifepristone (RU486) Affinity             AACGTGACACGTTCGGAGAATTTTTCGAAA-3 0 . <br />       Bioreagents; Staurosporine purchased Calbiochem             BglII HindIII restriction sites added sequences <br />       (Darmstadt, Germany).                                             used subsequent ligation pSUPER.                                                                         oligonucleotides annealed adding 3 mg                                                                         48 ml annealing buffer (100 mM sodium chloride, 50 mM <br />       Cell culture <br />                                                                         HEPES (pH 7.4)). mixture incubated 90 8C <br />       human lung epithelial carcinoma cell line, A549,          4 min, followed 70 8C 10 min. mixture       human liver carcinoma cell line, HepG2, 3T3L1 adipocyte           slowly cooled 10 8C. shRNA sequences       cells human embryonic kidney cell line, HEK293,           ligated pSUPER using T4 DNA ligase (Roche). <br />       obtained ECACC (Porton  UK). A549, <br />       HEK293 3T3-L1 cells maintained Dulbecco&#226;&#8364;&#8482;s <br />                                                                         Interaction Ska2 GR vitro <br />       modified Eagle&#226;&#8364;&#8482;s medium (DMEM) 10% foetal calf serum <br />       (FCS). HepG2 liver carcinoma cells maintained             GST GST-SKA2 expressed Escherichia coli strain <br />       Minimum Essential Medium (Eagle) containing Earl&#226;&#8364;&#8482;s salts          DH5a (Promega Corp.) purified described <br />       supplemented 10% FCS 1% non-essential amino              (Stevens et al. 2003). <br />       acids. CORL103, CORL24 DMS79 cells derived <br />       histologically confirmed bronchiogenic SCLC <br />                                                                         Western blotting <br />       (Pettengill et al. 1980, Baillie-Johnson et al. 1985). SCLC <br />       cells cultured RPMI 1640 medium (Sigma&#226;&#8364;&#8220;Aldrich),          Cells lysed using 1! RIPA buffer (100 mM Tris base, <br />       supplemented 2.5% FCS 10 mM HEPES (Ray et al.            150 mM NaCl, 1% Igepal, 2.5% sodium deoxycholate, 1 mM <br />       1994, 1996a). CEM-7A cells obtained Dr Ged              EDTA) tissues lysed using modified RIPA buffer (50 mM <br />       Brady (EpiStem  Manchester, UK) maintained             Tris&#226;&#8364;&#8220;HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium <br />       RPMI 1640 medium supplemented Glutamax (Invi-                deoxycholate, 1 mM EDTA, 0.1% SDS). buffers contained <br />       trogen) 10% FCS (Alourfi et al. 2005). Rat-1 cells       protease inhibitors (Complete, Roche Molecular Biochemicals). <br />       obtained ATCC maintained high glucose DMEM            Cell tissue extracts analysed SDS-PAGE western <br />       supplemented Glutamax (Invitrogen) 10% FCS.              blotting using following primary antibodies: 1:1000 SKA2 <br />  <br />       Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509                                                        www.endocrinology-journals.org <br />                                                                                       SKA2 interactions GR .          L RICE   501 <br />  <br /> rabbit polyclonal antibody (raised predicted <span id='am-32' about='obo:IMR_0001695' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-33' property="rdfs:label" content="amino acid" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:id" content="IMR:0001695" datatype="xsd:string"></span><span id='am-35' property="obo:IAO_0000115" content="Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins." datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasDbXref" content="CHEBI:33709" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasDbXref" content="MeSH:D000596" datatype="xsd:string"></span>amino acid</span>        Proliferation assays <br /> sequence) 1:2000 mouse monoclonal tubulin (DM1A, <br />                                                                       Cells seeded 96 plates treated indicated. <br /> Sigma&#226;&#8364;&#8220;Aldrich . specificity 14 kDa band detected <br />                                                                       Cell number estimated using MTS reagent (American <br /> using SKA2 antibody   confirmed using SKA2- <br />                                                                       Tissue Culture Collection) measured haemocytometer. <br /> specific blocking peptides, antibody incubated fivefold excess, weight, immunogenic peptide <br /> overnight 4 8C 1% milk blocking buffer.                         Immunohistochemistry human lung cancer <br />                                                                       Human SCLC xenografts obtained innoculating 108 <br /> Immunofluorescence                                                    DMS 79 cells Matrigel (1:1) subcutaneously flank <br />                                                                       athymic, nude mice. addition, panel human lung <br /> HEK293 cells infected GR-eYFP-expressing retro- <br />                                                                       cancer malignant mesotheliomas biopsy tissue <br /> virus A549 cells grown coverslips treated <br />                                                                       surplus requirements clinical diagnosis obtained DMSO (vehicle), Dex (100 nM) RU486                     patients Manchester Royal Infirmary Wythen- <br /> (100 nM) 1 h. cells washed 1! PBS               shawe Hospital, placed restriction use fixed 4% paraformaldehyde. Human lung tissue                 surplus tissue consented biopsy resection obtained North West Lung Centre, Medicines                   tumour. separate sections analysed Evaluation Unit, Wythenshawe Hospital, Manchester, UK.                tumour type. SKA2 staining quantitated triplicate fixation 4% paraformaldehyde, tissue sections          sections panel lung carcinomas using colour card <br /> cells permeabilized TD buffer (10 mM Tris&#226;&#8364;&#8220;HCl               (0&#226;&#8364;&#8220;3 intensity) compared  primary&#226;&#8364;&#8482; control <br /> (pH 8.0) 50 mM NaCl) blocked TD buffer                   masked observer. Data averaged containing 1% BSA 0.2% Triton X-100. 1:400 dilution             triplicates expressed intensity 0 3 SKA2 anti-peptide antibody   washing buffer           type carcinoma. <br /> (TD buffer plus 1% BSA 0.05% Triton X-100) added 2 h room temperature. Images taken using Bio- <br /> Rad MRC1024 confocal scanning Microscope, previously               Staining mitotic cells <br /> described (Garside et al. 2006).                                      Cells grown overnight coverslips mounted                                                                       4 0 ,6-diamidino-2-phenylindole-containing          mounting <br /> Quantification nuclear/cytoplasmic staining                        medium (Vectashield, Vector Laboratories  Peterborough, <br />                                                                       UK). Quantification mitotic figures performed using <br /> HEK293 cells triplicate slides separate experiments     fluorescent microscopy (excitation emission 360 scored nuclear cytoplasmic localization          460 nm respectively), field 100 cells counted Texas Red-conjugated proteins eYFP-tagged proteins.               percentage cells undergoing mitosis calculated. <br /> Treated untreated cells assigned &#226;&#8364;&#732;predominantly <br /> cytoplasmic&#226;&#8364;&#8482; (C) &#226;&#8364;&#732;predominantly nuclear&#226;&#8364;&#8482; (N) SKA2 GR-eYFP masked observer. numbers                  Breast array expressed percentage total cell number.              human breast tissue array described previously <br />                                                                       (Zhu et al. 2006). Detection FAM33A expression followed <br /> Generation stable cell lines                                       standard immunoperoxidase approach. Analysis                                                                       masked observer statistical comparison c2-test. cMyc-SKA2 plasmid DNA linearized transfected <br /> using FuGENE 6 (Roche). Cells incubated 1 mg/ml <br /> G418 sulphate. 2 weeks discrete colonies formed,          RNAi cloned screened gene expression western blot.         Short interfering siRNAs specific SKA2 custom <br />    create stable cell lines expressing shRNA, cells           designed using HiPerformance algorithm (Novartis transfected using FuGENE 6 (Roche) appropriate            Pharmaceuticals) synthesized (Qiagen . Sequences <br /> pSUPER vector vector pcDNA3  confer G418                   available request. <br /> resistance cell). 48 h transfection, growth medium cells supplemented 1 mg/ml G418 (Calbiochem). <br />                                                                       Microarray data analysis <br /> Colonies selected expanded G418 selection. <br />                                                                       Labelled cDNA hybridized HG-U133 PLUS2 <br />                                                                       oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). <br /> Reporter gene studies <br />                                                                       Technical quality control arrays check Cells transfected TAT3-luc reporter gene            outliers using dChip software (Li &amp; Wong 2001). Normal- <br /> analysed previously described (Stevens et al. 2003, Garside        ization expression analysis used robust multiple array <br /> et al. 2004, 2006).                                                   average (RMA; Bolstad et al. 2003). target effects  <br /> www.endocrinology-journals.org                                                                    Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509 <br />  502   L RICE   . SKA2 interactions GR <br />  <br />       expected siRNA experiments, independent siRNAs                   siRNA sequences <br />       used. experiment duplicate. Statistical <br />                                                                                  duplex sequences follows: siRNA #1 sense <br />       analysis performed comparing non-silencing control <br />                                                                                  strand r(CCC ACA GAA CCU AAA GUA dTCdT       combined siRNA samples group limma (Smyth                    antisense strand r(UUA CUU UAG GUU CUG UGG <br />       2004). False discovery rate correction performed                  G)dAdG; siRNA #3 sense strand r(GGC UGG AAU AUG <br />       QVALUE (Storey et al. 2004). Post-analysis performed                   AAA UCA dTdT antisense strand r(UUG AUU UCA <br />       using MAPPFinder Gene Ontology tool GenMapp 2.0                     UAU UCC AGC C)dTdG; siRNA #4 sense strand r(CGA <br />       software, San Francisco, CA, USA (Doniger et al. 2003),                    UUU AAA UAU AUG UAC dTdT antisense strand <br />       DAVID Bioinformatics Resources 2006 MetaCore                           r(UGU ACA UAU AUU UAA AUC G)dTdT. <br />       software (GeneGo, , St Joseph, MI, USA). microarray                   commercially available non-silencing control siRNA <br />       data submitted Minimum Information                       (Qiagen  transfected control target effects. <br />       Microarray Experiment-compliant format ArrayEx-                     sequence sense strand duplex UUC <br />       press database (http://www.ebi.ac.uk/arrayexpress/)                 UCC GAA CGU GUC ACG UdT dT antisense <br />       accession number assigned (E-MEXP-265).                                strand, ACG UGA CAC GUU CGG AGA AdT dT. <br />  <br />  <br />  <br />  <br />                       Figure 1 SKA2 interacts GR yeast vitro.   Yeast transformed reporter, GR &#226;&#8364;&#732;bait&#226;&#8364;&#8482;, <br />                       library clone R59 (encoding SKA2). single colony selected stock plate used create <br />                       liquid cultures yeast cells. incubated, triplicate, 3 h vehicle  ligand, NL), <br />                       50 mM dexamethasone (Dex) 50 mM RU486. cells lysed incubated CPRG <br />                       substrate. Background activity assays !1. (b) Evolutionary sequence comparison                       human rat mouse SKA2. Non-identical amino acids highlighted. (c) Autoradiograph                       GST &#226;&#8364;&#732;pull  [35S]GR incubated GST-SKA2 GST presence absence                       dexamethasone (50 mM) RU486 (50 mM). GST pulled resulting complexes resolved <br />                       SDS-PAGE. 35S-labeled GR bound GST fusion protein visualized phosphoimaging. <br />  <br />       Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509                                                                      www.endocrinology-journals.org <br />                                                                                         SKA2 interactions GR .         L RICE   503 <br />  <br />                                                                           Statistical analysis <br />                                                                           additional statistical analysis carried using SPSS <br />                                                                           (Chicago,  USA) Windows version 13.0. Specific tests <br />                                                                           described figure legends. <br />  <br />                                                                           Results <br />  <br />                                                                           Identification SKA2 GR-interacting protein <br />                                                                           identified SKA2 interacting C-terminal domain <br />                                                                           GR (amino acids 525&#226;&#8364;&#8220;777) yeast hybrid library <br />  <br />  <br />  <br />  <br /> Figure 2 SKA2 14 kDa protein expressed SCLC non- <br /> SCLC cell lines.   Western blot showing SKA2 protein expression <br /> using novel anti-peptide antibody. SKA2 immunogenic peptide <br /> (lane 1), endogenous SKA2 A549 cell lysate (lane 2), recombinant bacterially expressed GST-SKA2 (lane 3) detected bands 8, 14 42 kDa, predicted. Peptide- <br /> blocked antibody controls shown, indicated. (b) Western <br /> blot showing SKA2 expression cell lines tissues. A549 human <br /> non-SCLC cells, normal human lung tissue, DMS79 human SCLC <br /> cells, CORL24 human SCLC cells, HepG2 human liver carcinoma <br /> cells, mouse liver tissue, 3T3L1 mouse fibroblast cells, HEK293 <br /> human embryonic kidney cells, CEM-7A human T-lymphoblast <br /> cells, Rat-1 rat fibroblast cells, primary human skin fibroblast cells,   Figure 3 Expression SKA2 lung cancer.   Immunofluoresence <br /> AtT20 mouse pituitary cells, COS7 transformed monkey kidney               analysis SKA2 A549 cells basal treatment conditions <br /> fibroblast cells GH3 rat pituitary cells. (c) Western blot showing    indicated. (b) Immunoperoxidase staining SKA2 human <br /> SKA2 expression human breast cancer cell lines MCF-7,                  SCLC xenografts athymic mice primary human lung <br /> MCF-10A MDA-MB231, comparison A549 HeLa                   adenocarcinoma. Antibody controls (antibody blocked cells. (d) SKA2 protein expression A549 HEK293 cells               peptide primary) presented, indicated. Graph shows <br /> transfected expression vector (control)               small-scale pilot analysis SKA2 expression primary human <br /> cmyc-SKA2. Endogenous SKA2 14 kDa protein                    lung cancers. sections tumour scored <br /> exogenous cMyc-SKA2 18 kDa protein.                                 masked observer colour card (0&#226;&#8364;&#8220;3 intensity). <br />  <br /> www.endocrinology-journals.org                                                                     Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509 <br />  504   L RICE   . SKA2 interactions GR <br />  <br />       generated human SCLC cell line CORL103.                       Development antibody analysis endogenous SKA2 <br />       interaction GR SKA2 confirmed                           expression <br />       transformed yeast cells constitutive                                                                                  raised specific rabbit antibody human SKA2 (Fig. 2a). <br />       seen presence Dex RU486 (Fig. 1a). <br />                                                                                  SKA2 protein detected human SCLC NSCLC <br />          SKA2 encoded 831 <span id='am-24' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-25' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-29' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-30' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-31' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span>nucleotide</span> cDNA sequence, <br />       derives exon gene located human <br />       chromosome 17q 23.2 highly conserved (Fig. 1b). <br />       indications protein function amino <br />       acid sequence, homology known nuclear <br />       receptor modulators. <br />          confirm direct interaction GR       SKA2, used GST pull approach (Stevens et al. <br />       2003). clear interaction       proteins, little difference seen presence       Dex RU486 (Fig. 1c), predicted yeast studies. <br />  <br />  <br />  <br />  <br />                                                                                  Figure 5 SKA2 localizes GR moves nucleus                                                                                  Dex-treated cells.   Immunofluorescence HEK293 cells stably <br />                                                                                  expressing GR-eYFP, treated vehicle, Dex <br />                                                                                  (100 nM) RU486 (100 nM) indicated, 1 h fixation. <br />                                                                                  cells stained SKA2 using anti-peptide antibody, <br />       Figure 4 Expression SKA2 normal human lung tissue normal         peptide-blocking Texas Red-conjugated <br />       tumour sections breast tissue array.   Immunoperoxidase       secondary antibody. (b) Quantification SKA2 GR-EYFP <br />       staining SKA2 normal human lung  iv) low power, (ii     cytoplasmic nuclear distribution. Cells expressing GR-eYFP <br />       v) high power (iii vi) peptide adsorbed controls. Expression    selected analysis. total 46 untreated cells 101 <br />       seen epithelium (Ep), alveolar structures (Al) lymphoid follicles   treated cells separate experiments assigned <br />       (Ly). (b) Immunostaining SKA2 showed cytoplasmic staining         &#226;&#8364;&#732;predominantly cytoplasmic&#226;&#8364;&#8482; (C) &#226;&#8364;&#732;predominantly nuclear&#226;&#8364;&#8482; (N)       nuclear exclusion predominantly normal tissue. Staining     SKA2 GR-EYFP masked observer. Statistical analysis <br />       nucleus cytoplasm evident tumour samples.              used ANOVA followed Tukey&#226;&#8364;&#8220;Kramer post hoc test, <br />       peptide adsorbed control shown.                                         ***P!0.001. <br />  <br />       Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509                                                                    www.endocrinology-journals.org <br />                                                                                       SKA2 interactions GR .         L RICE   505 <br />  <br /> cells human cell lines, strikingly      Expression SKA2 human lung breast carcinomas <br /> human liver cell line HepG2 (Fig. 2b). immunoblot <br />                                                                         Immunofluorescence localized SKA2 mainly cytoplasm <br /> analysis revealed SKA2 expression breast cancer cell <br />                                                                         NSCLC cell line, A549 (Fig. 3a). Expression SKA2 <br /> lines HeLa cells (Fig. 2c). cmyc-SKA2                                                                         seen human SCLC xenografts (Fig. 3b) transfected HEK cells, endogenous transfected <br />                                                                         resected human lung adenocarcinoma. SKA2 forms SKA2 detected (Fig. 2d). <br />                                                                         detected selection primary human lung cancers                                                                         different histological types.  using sensitive <br />                                                                         immunoperoxidase technique, expression SKA2                                                                         seen non-tumourous human lung recovered                                                                         resection margins surgical specimens (Fig. 4a). <br />                                                                             high-level SKA2 expression seen breast cancer cell <br />                                                                         lines, expression sought breast tissue array. Expression                                                                         SKA2 easily detected specificity ensured using <br />                                                                         peptide adsorbed controls (Fig. 4b). lung cancer <br />                                                                         tissue samples, expression SKA2 normal <br />                                                                         cancerous breast (Fig. 4b) similar expression levels <br />                                                                         (mean intensity: 2.5 cancers 2.4 normal; PZ0.67). <br />                                                                          striking difference intracellular <br />                                                                         distribution SKA2 normal tumour tissue, <br />                                                                         greater proportion tumour cells having nuclear <br />                                                                         SKA2 compared normal breast (P!0.001). <br />  <br />                                                                         Intracellular localization SKA2 GR HEK293 cells <br />                                                                         distribution SKA2 cells appeared different <br />                                                                         normal tumour cells, studied localization relation <br />                                                                         GR. stained SKA2 expression using                                                                         antibody HEK293 cells infected GR-eYFP-expressing <br />                                                                         retrovirus analyzed untreated treated cells                                                                         immunofluorescence. GR cytoplasmic basal  <br /> Figure 6 SKA2 effects glucocorticoid function.   HepG2 cells transiently transfected SKA2, TAT3-luc reporter gene        ditions Dex, agonist, RU486, antagonist, CMV-renilla control plasmid treated triplicate        promoted nuclear translocation GR, expected (Fig. 5a range concentrations dexamethasone 16 h         b). SKA2 cytoplasmic basal conditions, <br /> harvest, luciferase assay. Corrected luciferase values         showing localization GR (Fig. 5a)  ligand- <br /> obtained expressed relative vehicle-treated control. <br /> Statistical analysis used ANOVA followed Tukey&#226;&#8364;&#8220;Kramer post           treated cells expressing high levels transgenic GR, hoc test, **P!0.01. Results representative experiments.    nuclear translocation SKA2, supporting Expression exogenous cMyc-SKA2 (18 kDa) shown inset            interaction proteins (Fig. 5). <br /> immunoblot. (b) SKA2 stably overexpressed HepG2 cells cells transiently transfected TAT3-luc treated dexamethasone triplicate  **P!0.01. Results representative experiments. (c) SKA2 protein expression wild-type A549 cells (wt), clone stably expressing non- <br /> silencing control shRNA (non-silencing control) clones <br /> stably expressing SKA2 shRNA. Clone1 displayed intermediate <br /> expression levels SKA2 clone 2 showed low levels expression, tubulin used loading control. (d) A549 cell <br /> clones expressing clone 2 (low SKA2 expression) non-silencing <br /> control transfected TAT3-luciferase reporter construct. 24 h, cells exposed range dexamethasone <br /> concentrations 24 h. Results normalized renilla control. Graph shows mean nZ3GS.E.M. analyzed ANOVA followed Bonferroni post hoc test, ***P!0.001. Results representative independent transfection experiments. (e)     Figure 7 Regulation FAM33A/SKA2.   Western blot SKA2 <br /> Effect dexamethasone (100 nM) total cell number A549           expression A549 cells treated dexamethasone (100 nM), <br /> cells assessed 5 days growth. Graph shows average       RU486 (100 nM), PMA (0.1 mM), Staurosporine (20 nM), Forskolin separate countsGS.E.M. Treatments compared using t-test,          (1 mM), TSA (HDAC inhibitor) (0.5 mM) respective vehicle <br /> ****P!0.0001, ***PZ0.004. Results representative             controls 18 h. (b) Western blot showing concentration response <br /> separate experiments, experiments assessed         SKA2 regulation dexamethasone (Dex). Results MTS.                                                                 representative separate experiments. <br />  <br /> www.endocrinology-journals.org                                                                   Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509 <br />  506   L RICE   . SKA2 interactions GR <br />  <br />       SKA2 modulates GR function                                               compared effect non-silencing control <br />                                                                                (Fig. 6d). <br />       effects SKA2 GR function determined                                                                                   examined effect SKA2 GC regulation       expressing SKA2 SKA2 null, HepG2 cells. transient            cell proliferation. Dex (100 nM) inhibited proliferation       transfection SKA2 reporter gene (Fig. 6a)               A549 cells 50%. clones moderate (clone 1) low <br />       introduction reporter cells stably overexpressing          (clone 2) expression SKA2, effect Dex abolished <br />       SKA2 (Fig. 6b) resulted potentiation GC transactivation.           (Fig. 6e). Importantly, effect altered SKA2 <br />          examination effects SKA2 GR function             expression basal proliferation. <br />       utilized knockdown SKA2 stable expression shRNA       A549 cells  shown express SKA2 protein, <br />       Fig. 2). generated clones expressing shRNA              Regulation SKA2 expression <br />       moderate (clone1) low (clone 2) residual expression SKA2           Analysis SKA2 gene locus did suggest       (Fig. 6c). Knockdown SKA2  clone 2) reversed                   expression regulated.  A549 cells treated <br />       GC-stimulated transactivation TAT3-luciferase reporter,           panel agents known affect cell survival                                                                                proliferation. examined effects various compounds <br />                                                                                SKA2 protein expression immunoblot. revealed <br />                                                                                marked inhibition SKA2 expression Dex, Staurosporine, <br />                                                                                phorbol ester TSA, induce apoptosis                                                                                inhibit cell proliferation A549 cells (Fig. 7). <br />  <br />                                                                                SKA2 potentiates cell proliferation <br />                                                                                determine effect SKA2 cell proliferation, non- <br />                                                                                expressing cell line, HepG2 (Fig. 2), transfected                                                                                SKA2 expression cassette stable clones selected <br />                                                                                (Fig. 8a). SKA2-expressing clone significantly <br />                                                                                enhanced proliferative response 24 h post-IGF                                                                                nearly twofold increase proliferation 48 h, compared <br />                                                                                control, significant differences seen <br />                                                                                non-stimulated conditions (Fig. 8b). <br />                                                                                   Knockdown SKA2 A549 cells caused cells held <br />                                                                                mitosis (Fig. 8c) evidenced percentage increase <br />                                                                                mitotic figures compared non-silencing <br />                                                                                control (Fig. 8d). <br />  <br />                                                                                Gene array profiling SKA2 function <br />                                                                                Initial studies identified specific siRNA sequences       Figure 8 SKA2 affects cell proliferation mitosis.   Western blot   potently inhibited SKA2 protein expression. separate <br />       showing stable expression cMyc-SKA2 HepG2 cells. SKA2- <br />       null HepG2 cells transfected cMyc-SKA2, clones       selected using neomycin screened cMyc-SKA2 expression <br />       immunoblot. Clones 1&#226;&#8364;&#8220;4 presented; clone 1 expressed SKA2. <br />        parental HepG2 cells; B, HEK293 cells transiently transfected <br />       cMyc-SKA2. Migration endogenous SKA2 HEK cells <br />       transgenic myc-tagged SKA2 marked. (b) MTT cell <br />       proliferation assay. Cells clone 1 non-expressing clone 4 <br />       serum starved 24 h treatment 5 nM IGF       triplicate. Cells assayed 24 48 h. Statistical <br />       analysis used ANOVA followed Tukey&#226;&#8364;&#8220;Kramer post hoc test, <br />       *PZ0.02, ***PZ0.0001. Results representative       experiments. (c) Mitotic figures. A549 clones expressing shRNA       SKA2 non-silencing control grown overnight cover-            Figure 9 effective siRNA molecules targeting SKA2       slips mounted DAPI-containing mounting medium; arrows             identified used microarray analysis compare       indicate mitotic cells. (d) Quantification mitotic figures.       transcriptional changes wild-type A549 cells A549 <br />       percentage cells undergoing mitosis calculated field       cells transfected SKA2 siRNA molecules. SKA2-specific <br />       100 cells. Graph shows average separate countsGS.E.M;        siRNAs transiently transfected cells concentrations <br />       t-test used Bonferroni correction multiple comparisons.     shown. siRNAs showed greater 80% SKA2 <br />       Wild-type compared clone 2, **PZ0.021; comparisons            knockdown 24 h (numbers 3 4). used       wild-type non-significant.                                     microarray analysis summarized Table 1. <br />  <br />       Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509                                                                   www.endocrinology-journals.org <br />                                                                                      SKA2 interactions GR .         L RICE   507 <br />  <br /> sequences sought allow additional refinement            involved mitosis (Hanisch et al. 2006). SKA2 required post-array analysis (Fig. 9). post-analysis purposes,            assembly condensed chromosomes metaphase plate <br /> relatively lenient q value threshold 0.2 produced 119 probe         (Hanisch et al. 2006).  turn, regulates spindle <br /> sets specifically significantly regulated        checkpoint silencing, allows exit SKA2-specific siRNAs. genes, SKA2 itself                  metaphase onset anaphase. SKA2 protein requires <br /> downregulated eightfold.                                               SKA1, protein binding partner, stability, SKA2    genes analysed enrichment Gene                    required correct assembly SKA1 kinetochore. <br /> Ontology categories GennMAPP (Doniger et al.                      cells depleted SKA proteins marked <br /> 2003), DAVID (Sherman et al. 2007) MetaCore                        delay progress mitosis, implying failure silence <br /> (GeneGo, ) softwares. SKA2 knockdown                 spindle checkpoint. suggests SKA proteins A549 cells resulted coordinate regulation pattern        role regulating progression mitosis. <br /> genes including gene products known involved cell                SKA2 expression multiple human lung <br /> cycle, apoptosis signalling (Table 1).                             cancer breast cancer cell lines primary tumours,                                                                        normal lung breast tissue. HepG2 cells expressed                                                                        detectable SKA2 protein, demonstrating high-level SKA2 <br /> Discussion                                                             expression universal feature transformed cells. Given <br />                                                                        (Hanisch et al. 2006) SKA2 genetic screen GR-interacting proteins             cytoplasm interphase cultured cells, interesting note <br /> SCLC identified SKA2. characterization                markedly higher nuclear localization SKA2 SKA2, independently discovered complex             breast cancer normal breast tissue. <br />  <br />  <br /> Table 1 Genes regulated SKA2 knockdown involved cell cycle, apoptosis signalling (SKA2 result included). Genes significantly  downregulated response &#226;&#8364;&#732;knockdown&#226;&#8364;&#8482; SKA2 expression specific siRNA. Statistical significance indicated q value <br />  <br />                   Entrez gene      Probe set <span id='am-39' about='oboInOwl:id' typeof='owl:Thing'>ID</span>      Fold change       q value          Gene title <br />  <br /> Gene symbol <br /> Downregulated <br />  SKA2             348 235          225684_at         K8.7              0.044            Family sequence similarity 33, member  ABCA1            19               203504_s_at       K2.9              0.033            <span id='am-13' about='obo:IMR_0001351' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-14' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasExactSynonym" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasAlternativeId" content="IMR:0200394" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="ATP" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:id" content="IMR:0001351" datatype="xsd:string"></span><span id='am-20' property="rdfs:label" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasDbXref" content="KEGG:C00002" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasExactSynonym" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasAlternativeId" content="IMR:0100127" datatype="xsd:string"></span>ATP</span>-binding cassette, sub-family (ABC1), <br />                                                                                            member 1 <br />  PPP2R1B          5519             202883_s_at       K2.6              0.110            Protein phosphatase 2  2A), regulatory <br />                                                                                            subunit  b isoform <br />  CCL2             6347             216598_s_at       K2.5              0.143            Chemokine (C-C motif) ligand 2 <br />  IL6ST            3572             204863_s_at       K2.2              0.110            Interleukin 6 signal transducer (gp130, oncostatin <br />                                                                                            M receptor) <br />  PPP2CA           5515             238719_at         K2.1              0.148            Protein phosphatase 2  2A), catalytic <br />                                                                                            subunit, isoform <br />  BMP2K            55 589           226853_at         K2.0              0.090            BMP2 inducible kinase <br />  EMR1             2015             207111_at         K2.0              0.185            EGF-like module containing, mucin-like, <br />                                                                                            hormone receptor-like 1 <br />  SOCS3            9021             227697_at         K1.9              0.198            Suppressor cytokine signalling 3 <br />  LRP12            29 967           220254_at         K1.9              0.143            Low density lipoprotein-related protein 12 <br />  RGS17            26 575           220334_at         K1.9              0.110            Regulator G-protein signalling 17 <br />  WWTR1            25 937           202132_at         K1.6              0.159            WW domain containing transcription regulator 1 <br />  WWTR1            25 937           202133_at         K1.5              0.166            WW domain containing transcription regulator 1 <br /> Upregulated <br />  NOVA1            4857             205794_s_at       1.5               0.185            Neuro-oncological ventral antigen 1 <br />  COL4A4           1286             214602_at         1.6               0.159            Collagen, type IV, 4 <br />  UNC5D            137 970          231325_at         1.7               0.169            Unc-5 homolog D (C. elegans) <br />  IGFBPL1          347 252          227760_at         1.8               0.193            IGF-binding protein-like 1 <br />  GRB10            2887             209409_at         1.8               0.169            Growth factor receptor-bound protein 10 <br />  G3BP2            9908             208841_s_at       1.8               0.159            GTPase activating protein (SH3 domain) binding <br />                                                                                           protein 2 <br />  PHACTR2          9749             227947_at         1.8               0.159            Phosphatase actin regulator 2 <br />  AI831506         &#226;&#8364;&#8220;                226520_at         2.0               0.091            Primary neuroblastoma cDNA, clone:Nbla11485 <br />   (Refseq) <br />  NOLC1            9221             211951_at         2.2               0.088            Nucleolar coiled-body phosphoprotein 1 <br />  CASP7            840              207181_s_at       2.5               0.159            Caspase 7, apoptosis-related cysteine peptidase <br />  MESDC2           23 184           224675_at         4.2               0.021            Mesoderm development candidate 2 <br />  <br />  <br /> www.endocrinology-journals.org                                                                  Journal Endocrinology (2008) 198, 499&#226;&#8364;&#8220;509 <br />  508   L RICE   . SKA2 interactions GR <br />  <br />          Unexpectedly, cells overexpressing GR       tissue. impact depletion SKA2 apoptotic-       construct, partial SKA2 translocation nucleus    proliferation-associated genes suggests SKA2 play       following GC treatment. suggests           role regulation cancer cell proliferation. <br />       functional interaction proteins       cytoplasm SKA2, lacks nuclear localization <br />       domain, &#226;&#8364;&#732;drawn&#226;&#8364;&#8482; nucleus movement      Declaration       GR.  effect appears require overexpression       GR seen clearly. suggests particular        authors declare conflict perceived <br />       conditions, seen breast cancer GR overexpression,    prejudicing impartiality research reported. <br />       nuclear exclusion SKA2 interphase lost, possible <br />       consequences cell proliferation survival. <br />          SKA2 interact GR, effect        <br />       GR transactivation function sought. Overexpressed <br />       SKA2 resulted modest enhancement GR transactivation,        <br />       knockdown SKA2 markedly inhibited GR                     <br />       transactivation. supports functional interaction            <br />       proteins. SKA2 appears role <br />       GC inhibition cell proliferation,  knockdown       SKA2 prevented decrease cell number seen Dex           <br />       treatment. <br />          SKA2 protein expression inhibited agents share    <br />       anti-proliferative pro-apoptotic actions A549 cells. Dex    <br />       profound inhibitory effects SKA2 expression         <br />       given GCs widely used induction phase       anti-cancer chemotherapy, implications cell <br />       cycle control appropriate chromosomal segregation,             <br />       interference spindle checkpoint (Hanisch <br />       et al. 2006).                                                  <br />          explore SKA2 function  overexpressed        <br />       SKA2 deficient cell line HepG2. significantly            <br />       enhanced proliferation following incubation IGF  <br />                                                                          <br />       suggests involvement SKA2 growth factor          <br />       signalling cell survival/proliferation pathways.        <br />       supported knockdown SKA2 A549 cells,                  <br />       produced increase cells arrested mitosis previously    <br />       shown HeLa S3 cells (Hanisch et al. 2006).                     <br />          Cells subjected transcript profiling genes    <br />       identified expression regulated SKA2             <br />       siRNAs, non-targeting siRNA. SKA2               <br />       transcript group genes markedly <br />                                                                          <br />       repressed, confirming success knockdown approach.       <br />       Functional grouping identified genes using gene ontology         <br />       approaches identified significant enrichment pathways            <br />       regulating cell survival, cell proliferation cytokine/   <br />       growth factor action, evidenced list significantly      <br />       regulated genes clustered pathways (Table 1).            <br />          conclude, identified functionally charac-         <br />       terized novel GR-interacting protein, isolated         <br />       human SCLC cell line. recently identified <br />                                                                          <br />       SKA2, protein involved regulating anaphase onset         <br />       HeLa S3 cells. studies SKA2 expressed          <br />       range cell lines human lung    <br />       breast cancer tissue. cells overexpressing GR, treatment         <br />       GC causes SKA2 localized GR         <br />       nucleus. Interestingly, SKA2 predominantly          <br />       nucleus breast tumours cytoplasm normal            <br /> </body></html>